Emerson (NYSE: EMR) is a global technology and software company providing innovative solutions for the world's essential industries. Through its leading automation portfolio, including its majority stake in AspenTech, Emerson helps hybrid, process and discrete manufacturers optimize operations, protect personnel, reduce emissions and achieve their sustainability goals.
The company is committed to its employees' wellbeing through a comprehensive benefits program, professional development opportunities, and a partnership with CuraLinc to provide personalized access to high-quality mental health care.
CuraLinc measured the health and productivity of Emerson employees who used the EAP in 2022. During the initial clinical assessment for each new EAP user, CuraLinc’s Care Advocates, all of whom are licensed mental health counselors, offered the SPS-6 and WOS to all employees; and offered the PHQ-9 and AUDIT to those who presented with depression and alcohol use, respectively. CuraLinc followed up with participants 30 days after the case was closed to measure changes in their health and productivity, evaluate their satisfaction with the program and profile for variations in health status or referrals to other resources.
88% of employees with depression showed improvement after using the program
|
82% of employees reported improved productivity
|
Employees who used the program missed 8.1 hours less work time
|
88% of employees who presented with alcohol use or abuse reported reduced risk
|
96% of participants reported satisfaction with the program
|
88% of employees with depression showed improvement after using the program | 82% of employees reported improved productivity | Employees who used the program missed 8.1 hours less work time | 88% of employees who presented with alcohol use or abuse reported reduced risk | 96% of participants reported satisfaction with the program |
CuraLinc uses clinically validated tools to measure the impact of the EAP, including the PHQ-9 for depression, the SPS-6 for productivity, the WOS for absenteeism and the AUDIT for alcohol abuse. These tools allow CuraLinc to establish quantifiable baselines and measure post-treatment outcomes from program participants — supporting the value of CuraLinc’s approach to providing evidence-based care through multiple modalities.
For Emerson, the partnership with CuraLinc led to lower rates of depression, higher productivity, reduced absenteeism and less risk of alcohol abuse — detailed in a case study titled, ‘EAP Outcomes and Impact.’
Want to learn more about CuraLinc and supports the emotional fitness of Emerson’s employees? Complete the form below to access the study.
.